ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Octreotide Sustained-release Formulation Debio 4126

Its studies are mostly in Acromegaly, led by Debiopharm.

Furthest: phase 3, since Apr 9, 20252 company-led studies, 1 open or runningNext primary completion: Jun 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Debiopharm21 open or runningphase 3since Apr 9, 2025May 4, 2022Jun 2028phase 3 · NCT06930625

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 4, 2022First study: phase 1 study in AcromegalyFirst studyNCT05364944 · 19 enrolled · Denmark, France, Germany and more
  2. Apr 9, 2025Phase 3 study in AcromegalyNCT06930625 · 119 planned · United States, Austria, Belgium and more

Ahead

  1. Jun 2028Primary completion: phase 3 study in AcromegalyNCT06930625

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06930625Acromegaly · United States, Austria, Belgium and more3RecruitingJun 2028119
NCT05364944Acromegaly · Denmark, France, Germany and more1TerminatedOct 29, 202419

How it is read

Names in the registry

  • “Debio 4126”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.